A specialty pharmaceutical company focused on the development and commercialization of difficult to make products.
About Us
Partnerships
Our aim is to be a partner that you can trust and foster relationships where the whole is greater than the sum of its parts.
Products
We focus on developing difficult generic and 505(b)(2) products. Through our strong domestic and global partnerships, products will include both patented and off-patented brands and generics.
Markets
We target products to the retail, institutional and specialty pharmaceutical markets. Prioritizing patient access is one of our key Company Values.
Our Pipeline
Epilepsy
Oral Solid
Launch: Q2 2022
Hypertension
Injection
Launch: Q3 2023
Acidosis
Injection
Launch: Q4 2022
Epilepsy
Oral Solid
Launch: Q2 2022
Hypertension
Injection
Launch: Q3 2023
Acidosis
Injection
Launch: Q4 2022
Contact Us
We’re happy to share more about the scope of our products, team, markets and answer questions. Reach out and we’ll schedule a time to connect.
We look forward to connecting.
Miscellaneous information:
IF YOU HAVE A MEDICAL EMERGENCY, PLEASE DIAL 911 IMMEDIATELY
CALL YOUR DOCTOR FOR MEDICAL ADVICE ABOUT SIDE EFFECTS. YOU MAY REPORT SIDE EFFECTS TO THE FDA AT 1-800-FDA-1088 (1-800-332-1088) OR Omnivium Pharmaceutical LLC AT 1-888-807-1048.
It is our corporate policy to provide technical information of prescription medicines to pharmacists and physicians only. If you are a patient seeking more detailed information about your prescription, please consult your doctor or pharmacist.
General Business Inquiries
Phone: 732-305-0726
Fax: 732-382-6880
Mail: 2131 Felver Ct, Suite A, Rahway, NJ 07065
Email: info@omniviumpharma.com
Product or Customer Related Inquiries
For Product Quality Complaints or Adverse Drug Events/Reactions, Product related/customer related inquiries, please contact us by:
Phone: 1 888-807-1048
Fax: 732-382-6880
Email: omnivium_micc@mitoconbiopharma.com